> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 receptor agonists and cancer risk in an umbrella review of 38 meta-analyses
- URL: https://www.coios.me/glp-1-receptor-agonists-and-cancer-risk-in-an-umbrella/
- Published: 2026-11-21T13:02:39.000Z
- Updated: 2026-11-21T16:38:43.000Z
- Description: In 48 placebo-controlled trials with 94 245 participants, GLP-1RAs showed no significant rise in overall or site-specific cancer.
- Author: Daniel Ryan
- Tags: Health today, Cancer, Obesity, diabetes and GLP-1, World, #peer-reviewed, #confirms, #item, #source-2026-11, #score-62

This umbrella review assessed cancer risk with GLP-1 receptor agonists and tirzepatide across 38 meta-analyses from 2012 to 2026\. Randomised and observational evidence were appraised separately for review quality, overlap and certainty. In 48 placebo-controlled trials with 94 245 participants, thyroid cancer showed no significant association (OR 1·37, 95% CI 0·82-2·31). Pancreatic, colorectal and breast cancer were also not significant, and overall cancer showed no increase (OR 1·05, 0·98-1·13). Observational syntheses suggested lower hepatocellular carcinoma risk (HR 0·60, 0·41-0·88), but four reviews overlapped heavily. No outcome reached high certainty, and median trial follow-up of about 70 weeks cannot address long-latency cancers.

*Why it is interesting: Cancer safety evidence for increasingly used GLP-1 drugs rests on trials with a median follow-up of about 70 weeks. Reviews disagreed on thyroid and colorectal cancer mainly through comparators, pooling methods and handling of zero-event trials.*

Source

[Cancer Epidemiology, 20 November 2026](https://doi.org/10.1016/j.canep.2026.103273?ref=coios.me)

DOI

10.1016/j.canep.2026.103273

Type

Peer-reviewed article

Design

Umbrella review of 38 meta-analyses (2012-2026) of GLP-1RA/tirzepatide and incident cancer, with AMSTAR 2, overlap (CCA), GRADE-informed certainty and Ioannidis credibility appraisal; largest randomised set 48-50 trials, 94,245 participants, median 70 weeks

Verdict

Confirms prior evidence

Driver

[Cancer](https://www.coios.me/d-cancer/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)